Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

Hdl Handle:
http://hdl.handle.net/10147/203189
Title:
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Authors:
Kavanagh, Dara O; Chambers, Gillian; O'Grady, Liam; Barry, Kevin M; Waldron, Ronan P; Bennani, Fadel; Eustace, Paul W; Tobbia, Iqdam
Affiliation:
Department of Surgery, Mayo General Hospital, Castlebar, Co Mayo, Ireland., dara_kav@hotmail.com
Citation:
BMC Cancer. 2009 Jan 1;9:1.
Journal:
BMC cancer
Issue Date:
31-Jan-2012
URI:
http://hdl.handle.net/10147/203189
DOI:
10.1186/1471-2407-9-1
PubMed ID:
19118499
Abstract:
BACKGROUND: The development of novel chemotherapeutic agents in colorectal cancer has improved survival. Following initial response to chemotherapeutic strategies many patients develop refractory disease. This poses a significant challenge common to many cancer subtypes. Newer agents such as Bevacizumab have successfully targeted the tyrosine kinase receptor epidermal growth factor receptor in metastatic colorectal cancer. Human epidermal growth factor receptor-2 is another member of the tyrosine kinase receptor family which has been successfully targeted in breast cancer. This may play a role in colorectal cancer. We conducted a clinicopathological study to determine if overexpression of human epidermal growth factor receptor-2 is a predictor of outcome in a cohort of patients with colorectal cancer. METHODS: Clinicopathological data and paraffin-embedded specimens were collected on 132 consecutive patients who underwent colorectal resections over a 24-month period at Mayo General Hospital. Twenty-six contained non-malignant disease. Her-2/neu protein overexpression was detected using immunohistochemistry (IHC). The HER-2 4B5 Ventana monoclonal antibody was used. Fluorescent insitu hybridisation (FISH) was performed using INFORM HER-2/Neu Plus. Results were correlated with established clinical and pathological predictors of outcome including TNM stage. Statistical analysis was performed using SPSS version 11.5. RESULTS: 114 were HER-2/Neu negative using IHC, 7 showed barely perceptible positivity (1+), 9 showed moderate staining (2+) and 2 were strongly positive (3+). There was no correlation with gender, age, grade, Dukes' stage, TNM stage, time to recurrence and 5-year survival (p > 0.05). FISH was applied to all 2+ and 3+ cases as well as some negative cases selected at random. Three were amplified (2 were 3+ and 1 was 2+). Similarly, HER-2 gene overexpression did not correlate with established prognostic indicators. CONCLUSION: HER-2 protein is over expressed in 11% of colorectal cancer patients. The gene encoding HER-2 is amplified in 3% of cases. Overexpression of HER-2 is not a predictor of outcome. However, patients who over express HER-2 may respond to Herceptin therapy.
Language:
eng
MeSH:
Adult; Aged; Aged, 80 and over; Cohort Studies; Colorectal Neoplasms/*diagnosis/genetics/*metabolism/pathology; Female; *Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Prognosis; Receptor, erbB-2/genetics/*metabolism
ISSN:
1471-2407 (Electronic); 1471-2407 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorKavanagh, Dara Oen_GB
dc.contributor.authorChambers, Gillianen_GB
dc.contributor.authorO'Grady, Liamen_GB
dc.contributor.authorBarry, Kevin Men_GB
dc.contributor.authorWaldron, Ronan Pen_GB
dc.contributor.authorBennani, Fadelen_GB
dc.contributor.authorEustace, Paul Wen_GB
dc.contributor.authorTobbia, Iqdamen_GB
dc.date.accessioned2012-01-31T15:54:58Z-
dc.date.available2012-01-31T15:54:58Z-
dc.date.issued2012-01-31T15:54:58Z-
dc.identifier.citationBMC Cancer. 2009 Jan 1;9:1.en_GB
dc.identifier.issn1471-2407 (Electronic)en_GB
dc.identifier.issn1471-2407 (Linking)en_GB
dc.identifier.pmid19118499en_GB
dc.identifier.doi10.1186/1471-2407-9-1en_GB
dc.identifier.urihttp://hdl.handle.net/10147/203189-
dc.description.abstractBACKGROUND: The development of novel chemotherapeutic agents in colorectal cancer has improved survival. Following initial response to chemotherapeutic strategies many patients develop refractory disease. This poses a significant challenge common to many cancer subtypes. Newer agents such as Bevacizumab have successfully targeted the tyrosine kinase receptor epidermal growth factor receptor in metastatic colorectal cancer. Human epidermal growth factor receptor-2 is another member of the tyrosine kinase receptor family which has been successfully targeted in breast cancer. This may play a role in colorectal cancer. We conducted a clinicopathological study to determine if overexpression of human epidermal growth factor receptor-2 is a predictor of outcome in a cohort of patients with colorectal cancer. METHODS: Clinicopathological data and paraffin-embedded specimens were collected on 132 consecutive patients who underwent colorectal resections over a 24-month period at Mayo General Hospital. Twenty-six contained non-malignant disease. Her-2/neu protein overexpression was detected using immunohistochemistry (IHC). The HER-2 4B5 Ventana monoclonal antibody was used. Fluorescent insitu hybridisation (FISH) was performed using INFORM HER-2/Neu Plus. Results were correlated with established clinical and pathological predictors of outcome including TNM stage. Statistical analysis was performed using SPSS version 11.5. RESULTS: 114 were HER-2/Neu negative using IHC, 7 showed barely perceptible positivity (1+), 9 showed moderate staining (2+) and 2 were strongly positive (3+). There was no correlation with gender, age, grade, Dukes' stage, TNM stage, time to recurrence and 5-year survival (p > 0.05). FISH was applied to all 2+ and 3+ cases as well as some negative cases selected at random. Three were amplified (2 were 3+ and 1 was 2+). Similarly, HER-2 gene overexpression did not correlate with established prognostic indicators. CONCLUSION: HER-2 protein is over expressed in 11% of colorectal cancer patients. The gene encoding HER-2 is amplified in 3% of cases. Overexpression of HER-2 is not a predictor of outcome. However, patients who over express HER-2 may respond to Herceptin therapy.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshColorectal Neoplasms/*diagnosis/genetics/*metabolism/pathologyen_GB
dc.subject.meshFemaleen_GB
dc.subject.mesh*Gene Expression Regulation, Neoplasticen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunohistochemistryen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshNeoplasm Stagingen_GB
dc.subject.meshPrognosisen_GB
dc.subject.meshReceptor, erbB-2/genetics/*metabolismen_GB
dc.titleIs overexpression of HER-2 a predictor of prognosis in colorectal cancer?en_GB
dc.contributor.departmentDepartment of Surgery, Mayo General Hospital, Castlebar, Co Mayo, Ireland., dara_kav@hotmail.comen_GB
dc.identifier.journalBMC canceren_GB
dc.description.provinceConnacht-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.